NASDAQ:CYTK
Cytokinetics Inc.
Cytokinetics Inc.'s revenue grew 376.6% in fiscal 2025 to $88.0M while operating margin rose to −695.4%. Free cash flow was −$534.8M, −607.5% of revenue, and the diluted share count rose 7.3%.Summary generated from Cytokinetics Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$88.0M
Revenue growth+376.6%
Revenue, 5-yr CAGR+9.5%
Gross marginn/a
Operating margin−695.4%
Net margin−891.6%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$534.8M
FCF margin−607.5%
Share count change+7.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 70 | 95 | 8 | 18 | 88 |
| Operating income | −186 | −324 | −496 | −536 | −612 |
| Net income | −215 | −389 | −526 | −590 | −785 |
| Free cash flow | −191 | −311 | −416 | −400 | −535 |
Recent filings
- 4Insider transaction report
Oct 6, 2026 - 4Insider transaction report
Sep 28, 2026 - 8-KOther events
Aug 28, 2026 - 8-KOther events
Aug 13, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KResults of a shareholder vote
May 27, 2026 - 8-KOther events
May 8, 2026